US Pfizer, India's Biocon scrap insulin pact

India's largest biotechnology firm, Biocon, and US pharmaceutical giant Pfizer said Tuesday they would scrap a joint plan to sell insulin products, sending Biocon's shares plunging.

Following the news Biocon shares fell as much as 11.09 percent to a low of 238 rupees on the Bombay Stock Exchange, before retracing partly to end the day at 250.8, still down 6.31 percent.

The companies said in a joint statement that the split was due to "individual priorities" for their respective businesses, adding it was "in their best interest to move forward independently". They did not elaborate.

"The development will have a psychological impact for Biocon. It cannot find a joint venture partner like Pfizer every day," Jagannadham Thunuguntla, head of research at SMC Global Securities, told AFP.

According to the deal struck in October 2010, Pfizer was to sell cheaper copies of diabetes products in some emerging markets and in Europe that the Bangalore-headquartered Biocon would make.

"With the Pfizer deal hitting the rocks, Biocon will have to scout for newer partners, especially for developed markets," said Sudarshan Padmanaban, analyst at Prabhudas Lilladher brokerage, in a note to investors.

The decision to abandon the plan comes at a time when multinational drug makers are increasingly tying up with Indian pharmas to source cheaper generic products for sale globally.

"Biocon will work with existing partners in several countries and pursue a commercial strategy on its own and through new alliances in other markets," its chairman Kiran Mazumdar Shaw said in the statement.

Pfizer's general manager Diem Nguyen said the firm would "continue in active research and business development for diabetes, which represents a huge unmet need".

add to favorites email to friend print save as pdf

Related Stories

US-based iGate to delist Indian unit Patni

Nov 16, 2011

US-based company iGate said Wednesday it plans to delist its unit Patni Computer Systems from stock exchanges by buying shares from the Indian company's public shareholders.

India's IT giant TCS slumps despite profit boost

Jan 18, 2012

Shares in India's biggest outsourcing firm TCS slid as much as 5.1 percent Wednesday amid investor concern about the outlook for a sector dependent on demand from crises-hit Europe and the United States.

Philips intends to sell LG.Philips LCD shares

Jul 08, 2005

LG.Philips LCD Co., Ltd., in which Royal Philips Electronics holds approximately 44.6 percent, last night announced that it has filed a Registration Statement with the U.S. Securities and Exchange Commission for a follow-on ...

Recommended for you

Supermaterial gives rejected drugs a new chance

8 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments